
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
k090257
B. Purpose for Submission:
Modification to device
C. Measurand:
Allergen Specific IgE (Cashew, Pistachio, Walnut, Clam, Oyster, Scallop, and Egg)
D. Type of Test:
Quantitative, chemiluminiscent immunoassay
E. Applicant:
Siemens Healthcare Diagnostics, Inc.
F. Proprietary and Established Names:
IMMULITE® 2000 3gAllergy™ Specific IgE Assay kit
G. Regulatory Information:
1. Regulation section:
21 CFR § 866.5750, Radioallergosorbent (RAST) test systems
2. Classification:
Class II
3. Product code:
DHB System, Test, Radioallergosorbent (RAST), Immunological
4. Panel:
Immunology (82)
H. Intended Use:
1. Intended use(s):
For in vitro diagnostic use with the IMMULITE 2000 Analyzer – for the
quantitative measurement of allergen-specific IgE in human serum, as an aid in
the clinical diagnosis of IgE-mediated allergic disorders.
2. Indication(s) for use:
Same as Intended use.
3. Special conditions for use statement(s):
For prescription use only.
4. Special instrument requirements:
IMMULITE 2000 Analyzer (k970227)
I. Device Description:
Each device contains the following: 3gAllergy™ specific IgE bead pack, alkaline
phosphatase conjugated to monoclonal murine anti-human IgE antibody in a
human/nonhuman serum buffer matrix, specific IgE adjustors and specific IgE
adjustor antibody, ligand-labeled polyclonal goat anti-human IgE antibody with
preservative; specific IgE universal kit controls and specific IgE control antibody.
J. Substantial Equivalence Information:
1. Predicate device name(s):
IMMULITE® 2000 3gAllergy™ Specific IgE
2. Predicate K number(s):
k013134
1

--- Page 2 ---
3. Comparison with predicates:
Similarities
Item New Device Predicate Device
Intended use For in vitro diagnostic use Same
with the IMMULITE 2000
Analyzer – for the
quantitative measurement of
allergen-specific IgE in
human serum, as an aid in the
clinical diagnosis of IgE-
mediated allergic disorders.
Technology Chemiluminescence Same
Assay Assay to be specific to Same
performance allergen-specific IgE
Calibrators Low and high Same
Controls Specific IgE Adjustor Same
Antibody, Specific IgE
Control Antibody and
Specific IgE Universal Kit
Controls
Sample type Serum Same
Result Quantitative values in kU/L; Same
Interpretation Interpretation of class results
for two scoring systems:
Standard and Extended
standard: refer to tables
attached below.
The Standard classification system utilizes the following class cutoffs:
Class kU/L Reactivity for Individual/Component Allergen(s)
< 0.10 Absent or ND†
0*
0.10 – 0.34 Very Low
I 0.35 – 0.69 Low
II 0.70 – 3.49 Moderate
III 3.50 – 17.49 High
IV 17.5 – 52.49
V 52.5 – 99.99 Very High
VI ≥ 100
* Class 0 in the standard system signifies: not detectable by second-generation assays.
† ND: not detectable by IMMULITE 2000 3gAllergy.
2

[Table 1 on page 2]
Similarities								
	Item			New Device			Predicate Device	
Intended use			For in vitro diagnostic use
with the IMMULITE 2000
Analyzer – for the
quantitative measurement of
allergen-specific IgE in
human serum, as an aid in the
clinical diagnosis of IgE-
mediated allergic disorders.			Same		
Technology			Chemiluminescence			Same		
Assay
performance			Assay to be specific to
allergen-specific IgE			Same		
Calibrators			Low and high			Same		
Controls			Specific IgE Adjustor
Antibody, Specific IgE
Control Antibody and
Specific IgE Universal Kit
Controls			Same		
Sample type			Serum			Same		
Result
Interpretation			Quantitative values in kU/L;
Interpretation of class results
for two scoring systems:
Standard and Extended
standard: refer to tables
attached below.			Same		

[Table 2 on page 2]
Class	kU/L	Reactivity for Individual/Component Allergen(s)
0*	< 0.10	Absent or ND†
	0.10 – 0.34	Very Low
I	0.35 – 0.69	Low
II	0.70 – 3.49	Moderate
III	3.50 – 17.49	High
IV	17.5 – 52.49	Very High
V	52.5 – 99.99	
VI	≥ 100	

--- Page 3 ---
The Extended standard classification system utilizes the following class cutoffs.
Class kU/L Reactivity for Individual/Component Allergen(s)
0 < 0.10 Absent or ND†
0/1 0.10 – 0.24 Very Low
I 0.25 – 0.39 Low
II 0.40 – 1.29 Moderate
III 1.30 – 3.89 High
IV 3.90–14.99
Very High
V 15.00– 24.99
VI ≥ 25
† ND: not detectable by IMMULITE 2000 3gAllergy.
The choice of classification systems can be made by the user within the IMMULITE
2000 operational software.
Reference: Hoffman, DR. Comparison of methods of performing the
Radioallergosorbent test: Phadebas, Fadal-Nalebuff and Hoffman protocols. Ann
Allergy. 1980 Dec; 45(6)
K. Standard/Guidance Document Referenced (if applicable):
Standard documents:
CLSI I/LA 20-A: Evaluation Methods and Analytical Performance Characteristics of
Immunological Assays for Human Immunoglobulin E (IgE)
CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Methods;
Approved Guideline – Second Edition
Guidance document:
FDA Guidance – Radioallergosorbent Test (RAST) Methods for Allergen-Specific
Immunoglobulin E (IgE) 510(k); Final Guidance
L. Test Principle:
The assay is a solid-phase, two-step, chemiluminiscent immunoassay that exploits
liquid phase kinetics in a bead format. The allergens are covalently bound to a soluble
polymer/co-polymer matrix, which is labeled with a ligand. The assay specific
antibody is labeled with alkaline phosphatase. The use of an amino acid co-polymer
amplifies the amount of allergen that the matrix can support. The chemiluminiscent
detection system is a phosphatase ester of stabilized dioxatane. Cleavage of the
phosphate ester by alkaline phosphatase results in the decomposition of dioxatane and
the emission of photons, which are quantified by a Luminometer.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Reproducibility of the assay was assessed by testing three positive samples
and one negative control sample of each allergen(Cashew, Pistachio, Walnut,
Clam, Oyster, Scallop, and Egg) in duplicate twice a day for 20 different days
(n = 80).
The sponsor’s criterion for the negative sample was the average dose must be
3

[Table 1 on page 3]
Class	kU/L	Reactivity for Individual/Component Allergen(s)
0	< 0.10	Absent or ND†
0/1	0.10 – 0.24	Very Low
I	0.25 – 0.39	Low
II	0.40 – 1.29	Moderate
III	1.30 – 3.89	High
IV	3.90–14.99	Very High
V	15.00– 24.99	
VI	≥ 25	

--- Page 4 ---
<0.10 kU/L; all negative sample results were within the acceptance criterion.
The sponsor’s acceptance criterion for the positive samples was ≤15% CV for
both within-run and total precision. Three allergen lots were tested for each
allergen; representative data from one lot is shown below for the positive
samples.
Allergen: Cashew
Sample Mean Intra-assay Inter-assay
(kU/L) SD %CV SD %CV
(kU/L) (kU/L)
Positive #1 5.20 0.20 3.8 0.27 5.2
Positive #2 9.46 0.42 4.5 0.56 6.0
Positive #3 4.13 0.16 3.9 0.24 5.8
Allergen: Pistachio
Sample Mean Intra-assay Inter-assay
(kU/L) SD %CV SD %CV
(kU/L) (kU/L)
Positive #1 14.14 0.60 4.2 0.82 5.8
Positive #2 4.33 0.21 4.9 0.28 6.5
Positive #3 1.76 0.08 4.5 0.11 6.0
Allergen: Walnut
Sample Mean Intra-assay Inter-assay
(kU/L) SD %CV SD %CV
(kU/L) (kU/L)
Positive #1 5.75 0.20 3.5 0.33 5.8
Positive #2 8.72 0.29 3.3 0.44 5.0
Positive #3 2.33 0.09 3.9 0.14 6.1
Allergen: Clam
Sample Mean Intra-assay Inter-assay
(kU/L) SD %CV SD %CV
(kU/L) (kU/L)
Positive #1 1.43 0.06 4.2 0.08 5.7
Positive #2 4.20 0.16 3.8 0.25 6.0
Positive #3 8.23 0.37 4.5 0.54 6.5
Allergen: Oyster
Sample Mean Intra-assay Inter-assay
(kU/L) SD %CV SD %CV
(kU/L) (kU/L)
Positive #1 13.18 0.72 5.4 0.92 6.9
Positive #2 0.74 0.03 4.3 0.04 5.7
Positive #3 5.32 0.24 4.6 0.36 6.7
4

[Table 1 on page 4]
Sample	Mean
(kU/L)		Intra-assay						Inter-assay				
			SD		%CV	%CV			SD		%CV	%CV	
			(kU/L)						(kU/L)				
Positive #1	5.20	0.20			3.8			0.27			5.2		
Positive #2	9.46	0.42			4.5			0.56			6.0		
Positive #3	4.13	0.16			3.9			0.24			5.8		

[Table 2 on page 4]
Mean
(kU/L)

[Table 3 on page 4]
Sample	Mean
(kU/L)		Intra-assay						Inter-assay				
			SD		%CV	%CV			SD		%CV	%CV	
			(kU/L)						(kU/L)				
Positive #1	14.14	0.60			4.2			0.82			5.8		
Positive #2	4.33	0.21			4.9			0.28			6.5		
Positive #3	1.76	0.08			4.5			0.11			6.0		

[Table 4 on page 4]
Mean
(kU/L)

[Table 5 on page 4]
Sample	Mean
(kU/L)		Intra-assay						Inter-assay				
			SD		%CV	%CV			SD		%CV	%CV	
			(kU/L)						(kU/L)				
Positive #1	5.75	0.20			3.5			0.33			5.8		
Positive #2	8.72	0.29			3.3			0.44			5.0		
Positive #3	2.33	0.09			3.9			0.14			6.1		

[Table 6 on page 4]
Mean
(kU/L)

[Table 7 on page 4]
Sample	Mean
(kU/L)		Intra-assay						Inter-assay				
			SD		%CV	%CV			SD		%CV	%CV	
			(kU/L)						(kU/L)				
Positive #1	1.43	0.06			4.2			0.08			5.7		
Positive #2	4.20	0.16			3.8			0.25			6.0		
Positive #3	8.23	0.37			4.5			0.54			6.5		

[Table 8 on page 4]
Mean
(kU/L)

[Table 9 on page 4]
Sample	Mean
(kU/L)		Intra-assay						Inter-assay				
			SD		%CV	%CV			SD		%CV	%CV	
			(kU/L)						(kU/L)				
Positive #1	13.18	0.72			5.4			0.92			6.9		
Positive #2	0.74	0.03			4.3			0.04			5.7		
Positive #3	5.32	0.24			4.6			0.36			6.7		

[Table 10 on page 4]
Mean
(kU/L)

--- Page 5 ---
Allergen: Scallop
Sample Mean Intra-assay Inter-assay
(kU/L) SD %CV SD %CV
(kU/L) (kU/L)
Positive #1 7.16 0.34 4.8 0.42 5.9
Positive #2 3.67 0.17 4.7 0.22 6.0
Positive #3 1.04 0.05 5.2 0.07 6.7
Allergen: Egg
Sample Mean Intra-assay Inter-assay
(kU/L) SD %CV SD %CV
(kU/L) (kU/L)
Positive #1 10.55 0.50 4.7 0.65 6.1
Positive #2 3.34 0.12 3.6 0.16 4.9
Positive #3 1.99 0.11 5.3 0.13 6.5
Lot to lot reproducibility:
Each of the seven allergens was tested as above with three positive samples
using three different lots (n = 240). Within-run imprecision for the
sample/allergen combinations ranged from 3.9% to 12.1%; total imprecision
of the sample/allergen combinations ranged from 5.1% to 12.5%.
b. Linearity/assay reportable range:
Linearity studies:
For each allergen, two samples were diluted in 2-fold serial dilutions to 5
levels. The undiluted (neat) and diluted samples were tested with the specific
allergen to demonstrate linearity at concentrations within the assay limits.
Regression statistics for each allergen comparing observed to expected results
are presented below.
Allergen Regression Equation N Slope 95% CI Intercept 95% CI
Cashew y= 1.00x + 0.19 12 1.00 0.98 – 1.02 0.19 - 0.04 – 0.41
Pistachio y= 1.00x – 0.32 12 1.00 0.99 – 1.02 - 0.32 -0.11 – 0.04
Walnut y= 1.00x – 0.11 12 1.00 0.99 – 1.02 - 0.11 -0.21 - -0.004
Clam y= 1.00x + 0.31 12 1.01 0.98 – 1.03 0.31 -0.21 – 0.83
Oyster y= 1.00x + 0.42 12 1.01 0.97 – 1.05 0.42 -0.26 – 1.10
Scallop y= 1.00x - 0.02 12 1.00 0.99 – 1.01 - 0.02 -0.17 – 0.13
Egg y = 1.00x + 0.097 12 1.00 0.99 – 1.01 0.10 -0.04 – 0.23
The assay working range is 0.1 – 100 kU/L.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
The calibrators and controls are traceable to the WHO 2nd IRP 75/502
reference standard.
5

[Table 1 on page 5]
Sample	Mean
(kU/L)	Intra-assay						Inter-assay				
		SD
(kU/L)		%CV	%CV			SD		%CV	%CV	
								(kU/L)				
Positive #1	7.16	0.34		4.8			0.42			5.9		
Positive #2	3.67	0.17		4.7			0.22			6.0		
Positive #3	1.04	0.05		5.2			0.07			6.7		

[Table 2 on page 5]
Mean
(kU/L)

[Table 3 on page 5]
Sample	Mean
(kU/L)	Intra-assay						Inter-assay				
		SD
(kU/L)		%CV	%CV			SD		%CV	%CV	
								(kU/L)				
Positive #1	10.55	0.50		4.7			0.65			6.1		
Positive #2	3.34	0.12		3.6			0.16			4.9		
Positive #3	1.99	0.11		5.3			0.13			6.5		

[Table 4 on page 5]
Mean
(kU/L)

[Table 5 on page 5]
Allergen	Regression Equation	N	Slope	95% CI	Intercept	95% CI
Cashew	y= 1.00x + 0.19	12	1.00	0.98 – 1.02	0.19	- 0.04 – 0.41
Pistachio	y= 1.00x – 0.32	12	1.00	0.99 – 1.02	- 0.32	-0.11 – 0.04
Walnut	y= 1.00x – 0.11	12	1.00	0.99 – 1.02	- 0.11	-0.21 - -0.004
Clam	y= 1.00x + 0.31	12	1.01	0.98 – 1.03	0.31	-0.21 – 0.83
Oyster	y= 1.00x + 0.42	12	1.01	0.97 – 1.05	0.42	-0.26 – 1.10
Scallop	y= 1.00x - 0.02	12	1.00	0.99 – 1.01	- 0.02	-0.17 – 0.13
Egg	y = 1.00x + 0.097	12	1.00	0.99 – 1.01	0.10	-0.04 – 0.23

--- Page 6 ---
Stability studies:
Accelerated allergen stability testing (15 – 28°C for 57 days; assay kits stored
at recommended temperature 2 – 8°C) supports a two-year shelf-life stability
claim. Real-time stability testing is underway and currently supports at least a
six month shelf-life.
d. Detection limit:
Analytical sensitivity: 0.1 kU/L
e. Analytical specificity:
Inhibition studies:
Specificity of each allergen was verified through competitive inhibition
testing using a single serum sample or pool of sera. A negative sample was
used to measure the background response. To initiate the inhibition
experiment, 70µL of undiluted and 4 levels of 5-fold serially diluted inhibitor
extract were mixed with 250 µL of sample or pool. This mixture was
incubated at room temperature (15-28°C) for 1 hour allowing the
immunological reaction to occur. Each sample mixture containing the
inhibitor extract and the appropriate controls was assayed with 1 lot of each
allergen. The percent (%) inhibition was calculated according to the following
formula:
(Response of pos. control – sample response with inhibitor extract)
(pos. sample – neg. sample) X 100
(Response of pos. control )
(pos. sample – neg. sample)
The inhibition study demonstrated that the allergens tested are inhibited by the
relevant inhibitor extract in a concentration dependent fashion. Summary
inhibition table is presented below.
Cashew Pistachio Walnut
Inhibitor % Inhibitor % Inhibitor %
Concentration Inhibition Concentration Inhibition Concentration Inhibition
(mg/mL) (mg/mL) (mg/mL)
5 100 5 98.8 5 100
1 98.6 1 96.8 1 92.4
0.2 95.1 0.2 89.6 0.2 78.9
0.04 90.3 0.04 76.6 0.04 57.6
0.008 82.9 0.008 71.7 0.008 48.3
Clam Oyster
Inhibitor % Inhibitor %
Concentration Inhibition Concentration Inhibition
(mg/mL) (mg/mL)
5 98.1 5 97.2
1 89.0 1 93.5
0.2 84.0 0.2 84.8
0.04 80.6 0.04 68.4
0.008 77.8 0.008 55.0
6

[Table 1 on page 6]
Cashew			Pistachio			Walnut	
Inhibitor
Concentration
(mg/mL)	%
Inhibition		Inhibitor
Concentration
(mg/mL)	%
Inhibition		Inhibitor
Concentration
(mg/mL)	%
Inhibition
5	100		5	98.8		5	100
1	98.6		1	96.8		1	92.4
0.2	95.1		0.2	89.6		0.2	78.9
0.04	90.3		0.04	76.6		0.04	57.6
0.008	82.9		0.008	71.7		0.008	48.3

[Table 2 on page 6]
Clam			Oyster	
Inhibitor
Concentration
(mg/mL)	%
Inhibition		Inhibitor
Concentration
(mg/mL)	%
Inhibition
5	98.1		5	97.2
1	89.0		1	93.5
0.2	84.0		0.2	84.8
0.04	80.6		0.04	68.4
0.008	77.8		0.008	55.0

--- Page 7 ---
Scallop Egg
Inhibitor % Inhibitor %
Concentration Inhibition Concentration Inhibition
(mg/mL) (mg/mL)
5 99.1 5 100
1 96.6 1 100
0.2 91.1 0.2 100
0.04 80.4 0.04 77.4
0.008 69.6 0.008 49.0
Cross-reactivity: The manufacturer states there is no detectable crossreactivity
with human serum immunoglobulins IgG, IgA, IgM or IgD at normal
physiological levels.
f. Assay cut-off:
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
Refer to Clinical studies
3. Clinical studies:
a. Clinical Sensitivity and specificity
Clinical performance of Cashew, Pistachio, Walnut, Clam, Oyster, Scallop,
and Egg allergens was demonstrated by testing samples from non-atopic and
atopic individuals with the IMMULITE® 2000 3gAllergy Specific IgE assay.
Atopic patients had documented history of allergy and/or skin-prick testing
(positive or negative). Sensitivity and specificity, based on diagnosis of atopic
status, are shown in the tables below:
Allergen: Cashew Clinical Diagnosis
Atopic Non-atopic Total
IMMULITE positive 18 0 18
2000 negative 21 100 121
Total 39 100 139
95% CI
Sensitivity: 46% 31 – 62%
Specificity: 100% 100 - 100%
7

[Table 1 on page 7]
Scallop			Egg	
Inhibitor
Concentration
(mg/mL)	%
Inhibition		Inhibitor
Concentration
(mg/mL)	%
Inhibition
5	99.1		5	100
1	96.6		1	100
0.2	91.1		0.2	100
0.04	80.4		0.04	77.4
0.008	69.6		0.008	49.0

[Table 2 on page 7]
Allergen: Cashew		Clinical Diagnosis		
		Atopic	Non-atopic	Total
IMMULITE
2000	positive	18	0	18
	negative	21	100	121
	Total	39	100	139

--- Page 8 ---
Allergen: Pistachio Clinical Diagnosis
Atopic Non-atopic Total
IMMULITE positive 23 5 28
2000 negative 16 116 132
Total 39 121 160
95% CI
Sensitivity: 59% 44 – 74%
Specificity: 96% 92 - 99%
Allergen: Walnut Clinical Diagnosis
Atopic Non-atopic Total
IMMULITE positive 20 1 21
2000 negative 19 152 171
Total 39 153 192
95% CI
Sensitivity: 51% 36 - 67 %
Specificity: 99% 98 - 101 %
Allergen: Clam Clinical Diagnosis
Atopic Non-atopic Total
IMMULITE positive 22 0 22
2000 negative 20 100 120
Total 42 100 142
95% CI
Sensitivity: 52% 37 - 71%
Specificity: 100% 100 -100%
Allergen: Oyster Clinical Diagnosis
Atopic Non-atopic Total
IMMULITE positive 24 9 33
2000 negative 18 107 125
Total 42 116 158
95% CI
Sensitivity: 55% 40 - 69%
Specificity: 92% 87 - 97%
8

[Table 1 on page 8]
Allergen: Pistachio		Clinical Diagnosis		
		Atopic	Non-atopic	Total
IMMULITE
2000	positive	23	5	28
	negative	16	116	132
	Total	39	121	160

[Table 2 on page 8]
Allergen: Walnut		Clinical Diagnosis		
		Atopic	Non-atopic	Total
IMMULITE
2000	positive	20	1	21
	negative	19	152	171
	Total	39	153	192

[Table 3 on page 8]
Allergen: Clam		Clinical Diagnosis		
		Atopic	Non-atopic	Total
IMMULITE
2000	positive	22	0	22
	negative	20	100	120
	Total	42	100	142

[Table 4 on page 8]
Allergen: Oyster		Clinical Diagnosis		
		Atopic	Non-atopic	Total
IMMULITE
2000	positive	24	9	33
	negative	18	107	125
	Total	42	116	158

--- Page 9 ---
Allergen: Scallop Clinical Diagnosis
Atopic Non-atopic Total
IMMULITE positive 22 0 22
2000 negative 20 153 173
Total 42 153 195
95% CI
Sensitivity: 52% 37 - 67%
Specificity: 100% 100 -100%
Allergen: Egg Clinical Diagnosis
Atopic Non-atopic Total
IMMULITE positive 13 13 26
2000 negative 5 140 145
Total 18 153 171
95% CI
Sensitivity: 72% 52 - 93%
Specificity: 92% 87 - 96%
b. Other clinical supportive data (when a. is not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not detected.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
9

[Table 1 on page 9]
Allergen: Scallop		Clinical Diagnosis		
		Atopic	Non-atopic	Total
IMMULITE
2000	positive	22	0	22
	negative	20	153	173
	Total	42	153	195

[Table 2 on page 9]
Allergen: Egg		Clinical Diagnosis		
		Atopic	Non-atopic	Total
IMMULITE
2000	positive	13	13	26
	negative	5	140	145
	Total	18	153	171